Rigel Pharmaceuticals Inc (RIGL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rigel Pharmaceuticals Inc (RIGL) has a cash flow conversion efficiency ratio of 0.056x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($21.98 Million) by net assets ($391.48 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Rigel Pharmaceuticals Inc - Cash Flow Conversion Efficiency Trend (1999–2025)
This chart illustrates how Rigel Pharmaceuticals Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read RIGL liabilities breakdown for a breakdown of total debt and financial obligations.
Rigel Pharmaceuticals Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rigel Pharmaceuticals Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Man Infraconstruction Limited
NSE:MANINFRA
|
0.007x |
|
TINC Comm VA
BR:TINC
|
0.022x |
|
Tianjin Binhai Energy & Development Co Ltd
SHE:000695
|
-0.336x |
|
Xiamen Comfort Science&Technology Group Co Ltd
SHE:002614
|
0.000x |
|
Gulf Oil Lubricants India Limited
NSE:GULFOILLUB
|
0.014x |
|
Nanjing Central Emporium Group Stocks Co Ltd
SHG:600280
|
0.109x |
|
Grape King Bio Ltd
TW:1707
|
0.014x |
|
Canadian Banc Corp
TO:BK
|
0.022x |
Annual Cash Flow Conversion Efficiency for Rigel Pharmaceuticals Inc (1999–2025)
The table below shows the annual cash flow conversion efficiency of Rigel Pharmaceuticals Inc from 1999 to 2025. For the full company profile with market capitalisation and key ratios, see Rigel Pharmaceuticals Inc (RIGL) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $391.48 Million | $75.66 Million | 0.193x | -97.98% |
| 2024-12-31 | $3.29 Million | $31.47 Million | 9.571x | +4673.90% |
| 2023-12-31 | $-28.64 Million | $-5.74 Million | 0.200x | -96.30% |
| 2022-12-31 | $-13.62 Million | $-73.76 Million | 5.417x | +2699.19% |
| 2021-12-31 | $30.37 Million | $5.88 Million | 0.194x | +112.62% |
| 2020-12-31 | $34.03 Million | $-52.19 Million | -1.534x | -98.83% |
| 2019-12-31 | $53.81 Million | $-41.51 Million | -0.771x | -44.07% |
| 2018-12-31 | $109.88 Million | $-58.83 Million | -0.535x | +30.52% |
| 2017-12-31 | $100.65 Million | $-77.56 Million | -0.771x | +44.12% |
| 2016-12-31 | $55.03 Million | $-75.89 Million | -1.379x | -438.27% |
| 2015-12-31 | $91.38 Million | $-23.41 Million | -0.256x | +52.89% |
| 2014-12-31 | $128.25 Million | $-69.75 Million | -0.544x | -31.61% |
| 2013-12-31 | $208.25 Million | $-86.06 Million | -0.413x | -40.24% |
| 2012-12-31 | $289.10 Million | $-85.19 Million | -0.295x | -0.31% |
| 2011-12-31 | $236.15 Million | $-69.38 Million | -0.294x | -204.41% |
| 2010-12-31 | $166.13 Million | $46.74 Million | 0.281x | +130.08% |
| 2009-12-31 | $109.87 Million | $-102.78 Million | -0.935x | +5.87% |
| 2008-12-31 | $104.17 Million | $-103.52 Million | -0.994x | -56.44% |
| 2007-12-31 | $82.18 Million | $-52.21 Million | -0.635x | -54.63% |
| 2006-12-31 | $87.23 Million | $-35.84 Million | -0.411x | -26.84% |
| 2005-12-31 | $108.59 Million | $-35.17 Million | -0.324x | +55.60% |
| 2004-12-31 | $52.30 Million | $-38.15 Million | -0.729x | +10.11% |
| 2003-12-31 | $39.97 Million | $-32.44 Million | -0.812x | +40.20% |
| 2002-12-31 | $25.44 Million | $-34.53 Million | -1.357x | -145.78% |
| 2001-12-31 | $28.94 Million | $-15.98 Million | -0.552x | -133.54% |
| 2000-12-31 | $49.01 Million | $-11.59 Million | -0.236x | +97.72% |
| 1999-12-31 | $756.00K | $-7.83 Million | -10.358x | -- |
About Rigel Pharmaceuticals Inc
Rigel Pharmaceuticals, Inc., a biotechnology company, develops and provides therapies that enhance the lives of patients with hematologic disorders and cancer in the United States. The company offers TAVALISSE, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia; REZLIDHIA, a non-intensive monotherapy to treat adult patients with relap… Read more